Advanced search
Publication Cover
Leukemia & Lymphoma Volume 19, 1995 - Issue 5-6
Submit an article Journal homepage
13
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Administration of rhG-CSF Increases Complete Remission Rates After CHOP and ProMACE/CytaBOM for Non-Hodghn's Lymphoma: A Pilot Study

Mihiro Okabe Third Department of Internal Medicine, Hokkaido University School of Medicine, Obihiro, Japan
,
Isao Maekawa Sapporo; Asahigawa Municipal Hospital, Obihiro, Japan
,
Sachiko Suzuki Third Department of Internal Medicine, Hokkaido University School of Medicine, Obihiro, Japan; Asahigawa Kousei Hospital, Obihiro, Japan
,
Masafumi Higuchi Sapporo Municipal Hospital, Obihiro, Japan
,
Masanobu Morioka Aiiku Hospital, Obihiro, Japan
,
Ken Nishi NTT Hospital, Obihiro, Japan
,
Toshiyuki Itaya Sapporo Kousei Hospital, Obihiro, Japan
,
Takumi Ohmura Asahigawa; Wakkanai Municipal Hospital, Wakkanai, Obihiro, Japan
,
Michitsugu Kawamura Hakodate Central Hospital, Hakodate, Obihiro, Japan
,
Nozomi Fuzimoto Kushiro Rosai Hospital, Kushiro, Obihiro, Japan
,
Atsushi Kato Obihiro Kousei Hospital, Obihiro, Japan
,
Mitsutoshi Kurosawa Third Department of Internal Medicine, Hokkaido University School of Medicine, Obihiro, Japan
,
Yasuyuki Kunieda Third Department of Internal Medicine, Hokkaido University School of Medicine, Obihiro, Japan
,
Tamotu Miyazaki Third Department of Internal Medicine, Hokkaido University School of Medicine, Obihiro, Japan
&
Masahiro Asaka Third Department of Internal Medicine, Hokkaido University School of Medicine, Obihiro, Japan
 show all
Pages 485-491 | Received 20 Jan 1995, Published online: 01 Jul 2009

References

  • Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Jr, Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl., J. Med. 1993; 328: 1002–6
  • Gottlieb J. A., Gutterman J. U., McCredie K. B., Rodriguez V., Frei E., III. Chemotherapy of Malignant lymphoma with adriamycin. Cancer Res. 1973; 33: 3024–8
  • McKelvey E. M., Gottlieb J. A., Wilson H. E., Haut A., Talley R. W., Stephens R., Lane M., Gamble J. F., Jones S. E., Grozea P. N., Gutterman J., Coltman, Jr., Moon T. E. Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–93
  • Jones S. E., Grozea P. N., Metz E. N., Haut A., Stephens R. L., Morrison F. S., Butler J. J., Byrne G. E., Jr, Moon T. E., Fisher R., Haskins C. L., Coltman C. A., Jr. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. Cancer 1979; 43: 417–25
  • Coltman C. A., Luce J. K., McKelvey E. M., Jones S. E., Moon T. E. Chemotherapy of non-Hodgkin's lymphoma: 10 year's experience in the Southwest Oncology Group. Cancer Treatment Report 1977; 61: 1067–78
  • Elias L., Portlock C. S., Rosenberg S. A. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1978; 42: 1705–10
  • Shipp M. A., Harrington D. P., Klatt M. M., et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Annals Int. Med. 1986; 104: 757–65
  • Fisher R., DeVita V. T., Jr, Hubbard S. M. Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc. Am. Soc. Clin. Oncol. 1984; 3: 242, abstr
  • Klimo P., Connors I. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Annals Int. Med. 1985; 102: 596–602
  • Kuni-Eda Y., Okabe M., Kurosawa M., Maekawa I., Higuchi M., Kawamura M., Morioka M., Suzuki S., Ohmura T., Fujimoto N., Matsuno K., Nakane K., Minagawa T., Miyaraki T., Sakurada K. Effect of rhG-CSF on infection complications and impaired function of neutrophil secondary to chemotherapy for non-Hodgkin's lymphoma. Leuk. Lymph. 1994, in press
  • The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggresive non-Hodgkin's lymphoma. New Engl. J. Med. 1993; 329: 987–994
  • Longo D. L., Duffy P. L., De Vita V. T., Wesley M. N., Jr., Hubbard S. M., Young R. C. The calculation of actual or recieved dose intensity: A comparison of published methods. J. Clin. Oncol. 1991; 9: 2042–2051
  • Coleman M. Chemotherapy for the treatment of diffuse large-cell lymphoma. Annals Int. Med. 1985; 102: 596–602
  • Tanosaki R., Okamoto S., Akatsuka N., Kawai Y., Ikeda Y. Dose-escalation study of biweekly CHOP using recombinant human granulocyte-colony stimulating-factor (RHG-CSF) in non-Hodgkin's lymphorna. Blood 1993; 82 (Suppl.): 144, abstr
  • Shipp M. A., Shulman L. N., Kaplan W. D., Neuberg D., Canellos G. P. Intensified induction therapy for patients with “high-risk” aggressive NHL: High dose CHOP. Blood 1993; 82(Suppl.)332, abstr

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.